Get all your news in one place.

100's of premium titles.
One app.

Start reading

Get all your news in one place.

100's of premium titles. One news app.

Start reading

INSANE: 4 - The Real Truth

ARWR: Phase 3 PALISADE Study of ARO-APOC3 Underway…

By David Bautz, PhD NASDAQ:ARWR READ THE FULL ARWR RESEARCH REPORT

Benzinga

POET: Could POET's Biggest Market Be AI Accelerators?

By Lisa Thompson NASDAQ:POET READ THE FULL POET RESEARCH REPORT

Benzinga

LGVN: CEO Leaving but Progress Continues

By Brad Sorensen, CFA NASDAQ:LGVN READ THE FULL LGVN RESEARCH REPORT

Benzinga

From analysis to the latest developments in health,
read the most diverse news in one place.

ACHV: First Quarter 2022 Results

By John Vandermosten, CFA NASDAQ:ACHV READ THE FULL ACHV RESEARCH REPORT

Benzinga

COCP: Cocrystal Pharma Releases 2022 1st Quarter Results and Provides an Update on the Current Pipeline Programs

By Thomas Kerr, CFA NASDAQ:COCP READ THE FULL COCP RESEARCH REPORT

Benzinga

CXW: Benefit of Strong Balance Sheet in Rising Interest Rate Environment

By M. Marin NYSE:CXW READ THE FULL CXW RESEARCH REPORT Recent trends illustrate stability of revenue streams

Benzinga

LPCN: First Quarter 2022 Financial and Operational Results

By John Vandermosten, CFA NASDAQ:LPCN READ THE FULL LPCN RESEARCH REPORT

Benzinga

Read news from The Economist, FT, and more,
with one subscription

AEMD: Effectiveness of Hemopurifier on COVID-19 Variants In Vitro Indicates Device's Potential Range

By M. Marin NASDAQ:AEMD READ THE FULL AEMD RESEARCH REPORT

Benzinga

VIVXF: OxC-beta Approved in Vietnam…

By David Bautz, PhD OTC:VIVXF READ THE FULL VIVXF RESEARCH REPORT

Benzinga

BVXV: Definitive Collaboration Agreement Signed to Develop Pipeline of NanoAb Therapies…

By David Bautz, PhD NASDAQ:BVXV READ THE FULL BVXV RESEARCH REPORT

Benzinga

ECOR: First Quarter 2022 Financial and Operational Results

By John Vandermosten, CFA NASDAQ:ECOR READ THE FULL ECOR RESEARCH REPORT

Benzinga

MDXG: 1Q:22 Financial and Operational Results

By John Vandermosten, CFA NASDAQ:MDXG READ THE FULL MDXG RESEARCH REPORT

Benzinga

LTRN: First Quarter 2022 Financial and Operational Results

By John Vandermosten, CFA NASDAQ:LTRN READ THE FULL LTRN RESEARCH REPORT

Benzinga

POET: POET Technologies Continues to Add Customers and Development Projects

By Lisa Thompson NASDAQ:POET READ THE FULL POET RESEARCH REPORT

Benzinga

Get all your
news in one place.

100's of premium titles.
One news app.

Benzinga

MHH: Mastech Digital Reports Q1 Revenue Growth of 20% and Reaps Rewards of a Tight Labor Market

By Lisa Thompson NYSE:MHH READ THE FULL MHH RESEARCH REPORT

Benzinga

ACHV: Topline Data from ORCA-2 Smoking Cessation Trial

By John Vandermosten, CFA NASDAQ:ACHV READ THE FULL ACHV RESEARCH REPORT

Benzinga

QNRX: FDA Clearance To Move QRX003 Clinical Testing Forward; Positive Implications

By M. Marin NASDAQ:QNRX READ THE FULL QNRX RESEARCH REPORT

Benzinga

EPIX: Preclinical Data on Androgen Receptor N-Terminal Domain Degrader Presented at AACR…

By David Bautz, PhD NASDAQ:EPIX READ THE FULL EPIX RESEARCH REPORT

Get all your
news in one place.

100's of premium titles.
One news app.

Benzinga

TRC: Expanding Development Partnership Highlights Company's Strong Prospects

By M. Marin NYSE:TRC READ THE FULL TRC RESEARCH REPORT

Benzinga

ALQGC: New Capital and New Investors Added

By John Vandermosten, CFA EPA:ALQGC READ THE FULL ALQGC RESEARCH REPORT

Benzinga

ORMP: Broadening IP Protection, Positive Physician Indicators & Studies Advancing

By M. Marin NASDAQ:ORMP READ THE FULL ORMP RESEARCH REPORT Broadening patent IP protection…

Benzinga

CXW: Potential Impact of Title 42 Repeal

By M. Marin NYSE:CXW READ THE FULL CXW RESEARCH REPORT

Benzinga

NVX: Rising EV Adoption & Charging Infrastructure Buildout Are Positives As NVX Ramps Production Capacity

By M. Marin NASDAQ:NVX READ THE FULL NVX RESEARCH REPORT

Benzinga

QLGN: Secures Worldwide Rights to G4-Selective Cancer Therapeutics…

By David Bautz, PhD NASDAQ:QLGN READ THE FULL QLGN RESEARCH REPORT

Benzinga

ALVOF: Alvopetro Energy's Management Focused on Advancing the Murucututu/Gomo natural gas Project to Production; Operational Capacity of the Gas Processing Facility Scheduled to Increase by 25% in June

By Steven Ralston, CFA OTC:ALVOF | TSX:ALV.V READ THE FULL ALVOF RESEARCH REPORT

1 … 3 4 5 6

People

From analysis to the latest developments in health,
read the most diverse news in one place.

Organisations

Department of Defense

US Customs and Border Protection

Read news from The Economist, FT, and more,
with one subscription

Topics

Places

Fourteen days free

Download the app

One app. One membership.
100+ trusted global sources.